Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / HCM - Hutchmed gets approval to market Elunate for colorectal cancer in Macau

HCM - Hutchmed gets approval to market Elunate for colorectal cancer in Macau

HUTCHMED (China) Limited
Hutchmed (China) (NASDAQ:HCM) received approval to market fruquintinib (sold as Elunate in China) to treat metastatic colorectal cancer in the Macau Special Administrative Region. The approval follows the latest update to the provisions on new drug importation which allows drugs that have been approved in one or more specified jurisdictions to be authorized for use in Macau. Priviously, regulations required approval from at least two other jurisdictions. Fruquintinib was approved in Mainland China by the National Medical Products Administration (NMPA) in September 2018 to treat metastatic colorectal cancer. The company said Elunate will become the first homegrown innovative oncology drug to be marketed in Macau based on its approval by the NMPA.

For further details see:

Hutchmed gets approval to market Elunate for colorectal cancer in Macau
Stock Information
Company Name: HUTCHMED (China) Limited
Stock Symbol: HCM
Market: NASDAQ
Website: hutch-med.com
Menu
HCM HCM Quote HCM Short HCM News HCM Articles HCM Message Board
Get HCM Alerts

News, Short Squeeze, Breakout and More Instantly...